vismodegib,atezolizumab,vemurafenib,pertuzumab,cobimetinib,alectinib
daiichi sankyo,roche
['mypathway']
the result of the tumor agnostic mypathway basket trial showed heterogenous response rate but promising results in some mutation/amplification/condition such as the alk rearrangement and high tmb. #esmo22 
????? IM resident @MountSinaiNYC. ???????? Aspiring a med-onc physician scientist. Interested in drug development. Dog lover. Tweets are my own.